

Gavin R Screaton

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4095111/gavin-r-screaton-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

9,915
citations

45
h-index

99
g-index

165
ext. papers

14,496
ext. citations

21.1
avg, IF

5.87
L-index

#	Paper	IF	Citations
103	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. <i>Nature Immunology</i> , 2016 , 17, 1102-8	19.1	637
102	Cross-reacting antibodies enhance dengue virus infection in humans. <i>Science</i> , 2010 , 328, 745-8	33.3	624
101	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020 , 21, 1336-1345	19.1	615
100	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. <i>Nature Medicine</i> , 2003 , 9, 921-7	50.5	609
99	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021 , 184, 2348-2361.e6	56.2	549
98	Structural basis of potent Zika-dengue virus antibody cross-neutralization. <i>Nature</i> , 2016 , 536, 48-53	50.4	362
97	T cell responses to whole SARS coronavirus in humans. <i>Journal of Immunology</i> , 2008 , 181, 5490-500	5.3	344
96	A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. <i>Nature Immunology</i> , 2015 , 16, 170-177	19.1	309
95	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021 , 184, 4220-4236.e13	56.2	296
94	MAIT cells are activated during human viral infections. <i>Nature Communications</i> , 2016 , 7, 11653	17.4	283
93	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021 , 184, 2939-2954.e9	56.2	281
92	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021 , 184, 2201-2211.e7	56.2	269
91	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. <i>Nature</i> , 2015 , 520, 109-13	50.4	234
90	Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. <i>Journal of Experimental Medicine</i> , 1999 , 189, 1489-96	16.6	219
89	Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. <i>Nature Structural Biology</i> , 1999 , 6, 1048-53		214
88	New insights into the immunopathology and control of dengue virus infection. <i>Nature Reviews Immunology</i> , 2015 , 15, 745-59	36.5	212
87	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , 2020 , 20, 1390-1400	25.5	212

86	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020 , 28, 445-454.e6	23.4	187
85	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. <i>Nature Structural and Molecular Biology</i> , 2020 , 27, 950-958	17.6	175
84	Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 16922-7	11.5	174
83	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. <i>Cell</i> , 2022 ,	56.2	154
82	An in-depth analysis of original antigenic sin in dengue virus infection. <i>Journal of Virology</i> , 2011 , 85, 410-416	8.6	145
81	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021 , 184, 2183-2200.e22	56.2	145
80	Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. <i>ELife</i> , 2020 , 9,	8.9	122
79	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020 , 5, 139	4.8	120
78	The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2021 , 73, e699-e709	11.6	120
77	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.. <i>Lancet, The</i> , 2021 ,	40	115
76	HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. <i>Journal of Experimental Medicine</i> , 2004 , 200, 1547-57	16.6	96
75	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. <i>Journal of Infectious Diseases</i> , 2018 , 218, 536-545	7	95
74	Antibodies and tuberculosis. <i>Tuberculosis</i> , 2016 , 101, 102-113	2.6	93
73	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. <i>Blood</i> , 1999 , 93, 1506-1510	2.2	90
72	The immune response against flaviviruses. <i>Nature Immunology</i> , 2018 , 19, 1189-1198	19.1	82
71	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. <i>Nature Immunology</i> , 2017 , 18, 1261-1269	19.1	74
70	Cardiovascular manifestations of the emerging dengue pandemic. <i>Nature Reviews Cardiology</i> , 2014 , 11, 335-45	14.8	70
69	Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. <i>Journal of Neurochemistry</i> , 2000 , 74, 490-500	6	68

68	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021 , 398, 981-990	40	68
67	Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. <i>Journal of Immunology</i> , 2012 , 188, 4971-9	5.3	65
66	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021 , 184, 5699-5714.e11	56.2	64
65	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV,the</i> , 2021 , 8, e474-e485	7.8	62
64	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018 , 9, 2441	17.4	51
63	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. <i>Nature Communications</i> , 2017 , 8, 15411	17.4	48
62	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021 , 7, 594-602	16.8	47
61	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.. <i>Lancet, The</i> , 2022 ,	40	46
60	Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells. <i>PLoS Pathogens</i> , 2014 , 10, e1004434	7.6	43
59	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. <i>Transfusion Medicine</i> , 2021 , 31, 167-175	1.3	42
58	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020 , 5, 181	4.8	38
57	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021 , 12, 2055	17.4	37
56	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. <i>Eurosurveillance</i> , 2020 , 25,	19.8	36
55	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. <i>Nature Medicine</i> , 2018 , 24, 721-723	50.5	35
54	A simplified positive-sense-RNA virus construction approach that enhances analysis throughput. <i>Journal of Virology</i> , 2013 , 87, 12667-74	6.6	34
53	Recent advances in human flavivirus vaccines. <i>Current Opinion in Virology</i> , 2017 , 23, 95-101	7.5	33
52	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. <i>Nature Immunology</i> , 2019 , 20, 1291-1298	19.1	33
51	Recent advances in understanding dengue. <i>F1000Research</i> , 2016 , 5,	3.6	31

50	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. <i>Clinical Infectious Diseases</i> , 2021	11.6	31
49	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2021 ,	40	30
48	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. 2021 ,		25
47	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021 , 12, 1951	17.4	25
46	Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8 T cell response. <i>Nature Immunology</i> , 2017 , 18, 1228-1237	19.1	22
45	The immunopathology of dengue and Zika virus infections. <i>Current Opinion in Immunology</i> , 2017 , 48, 1-6	7.8	22
44	Synovial IL-21/TNF-producing CD4 T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 775-783	6.5	22
43	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. <i>Nature Immunology</i> , 2018 , 19, 1248-1256	19.1	21
42	An immunodominant NP-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. <i>Nature Immunology</i> , 2021 ,	19.1	19
41	Endothelial Nitric Oxide Pathways in the Pathophysiology of Dengue: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1453-1461	11.6	16
40	Invariant NKT cell response to dengue virus infection in human. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e2955	4.8	16
39	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. <i>Nature Communications</i> , 2020 , 11, 5278	17.4	16
38	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status		16
37	Microvascular and endothelial function for risk prediction in dengue: an observational study. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S102	40	15
36	The immunology of Zika Virus. <i>F1000Research</i> , 2018 , 7, 203	3.6	15
35	Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. <i>Journal of Virology</i> , 2018 , 92,	6.6	15
34	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. <i>Blood</i> , 1999 , 93, 1506-1510	2.2	14
33	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. <i>Cell Host and Microbe</i> , 2021 ,	23.4	14

32	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
31	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , 2021 , 12, 6250	17.4	13
30	Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine 2021 ,		13
29	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	10.2	12
28	Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. <i>BMC Infectious Diseases</i> , 2021 , 21, 187	4	12
27	Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins. <i>Nature Communications</i> , 2021 , 12, 1238	17.4	12
26	T cell Responses and Dengue Haemorrhagic Fever. <i>Novartis Foundation Symposium</i> , 2008 , 164-176		11
25	T cell responses and dengue haemorrhagic fever. <i>Novartis Foundation Symposium</i> , 2006 , 277, 164-71; discussion 171-6, 251-3		11
24	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.. <i>Nature Medicine</i> , 2022 ,	50.5	11
23	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. <i>Cell Reports</i> , 2019 , 26, 1585-1597.e4	10.6	9
22	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. <i>Eurosurveillance</i> , 2020 , 25,	19.8	9
21	Autoantibody-dependent amplification of inflammation in SLE. <i>Cell Death and Disease</i> , 2020 , 11, 729	9.8	9
20	High flavivirus structural plasticity demonstrated by a non-spherical morphological variant. <i>Nature Communications</i> , 2020 , 11, 3112	17.4	8
19	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. <i>Vaccines</i> , 2020 , 8,	5.3	8
18	HIV-1 Nef: negative effector of Fas?. <i>Nature Immunology</i> , 2001 , 2, 384-5	19.1	8
17	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies		8
16	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses		7
15	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.. <i>Journal of Infection</i> , 2022 ,	18.9	7

14	Evolution of neurovirulent Zika virus. <i>Science</i> , 2017 , 358, 863-864	33.3	6
13	The Influence of CD25+ Cells on the Generation of Immunity to Tumour Cell Lines in Mice. <i>Novartis Foundation Symposium</i> , 2008 , 149-157		6
12	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2		6
11	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses		6
10	The epitope arrangement on flavivirus particles contributes to Mab C10B extraordinary neutralization breadth across Zika and dengue viruses. <i>Cell</i> , 2021 , 184, 6052-6066.e18	56.2	5
9	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.. <i>EBioMedicine</i> , 2022 , 77, 103902	8.8	5
8	Author response: Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study 2020 ,		4
7	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity		4
6	Human antibody C10 neutralizes by diminishing Zika but enhancing dengue virus dynamics. <i>Cell</i> , 2021 , 184, 6067-6080.e13	56.2	3
5	Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. <i>Frontiers in Immunology</i> , 2018 , 9, 1621	8.4	3
4	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum		3
3	A high resolution view of an adolescent flavivirus		2
2	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> ,	1	2
1	Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.. <i>MSphere</i> , 2022 , e0091321	5	0